The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
The Discovery of the Microsomal Ethanol Oxidizing System and Its Physiologic and Pathologic Role
Abstract
Oxidation of ethanol via alcohol dehydrogenase (ADH) explains various metabolic effects of ethanol but does not account for the tolerance. This fact, as well as the discovery of the proliferation of the smooth endoplasmic reticulum (SER) after chronic alcohol consumption, suggested the existence of an additional pathway which was then described by Lieber and DeCarli, namely the microsomal ethanol oxidizing system (MEOS), involving cytochrome P450. The existence of this system was initially challenged but the effect of ethanol on liver microsomes was confirmed by Remmer and his group. After chronic ethanol consumption, the activity of the MEOS increases, with an associated rise in cytochrome P450, especially CYP2E1, most conclusively shown in alcohol dehydrogenase negative deer mice. There is also cross-induction of the metabolism of other drugs, resulting in drug tolerance. Furthermore, the conversion of hepatotoxic agents to toxic metabolites increases, which explains the enhanced susceptibility of alcoholics to the adverse effects of various xenobiotics, including industrial solvents. CYP2E1 also activates some commonly used drugs (such as acetaminophen) to their toxic metabolites, and promotes carcinogenesis. In addition, catabolism of retinol is accelerated resulting in its depletion. Contrasting with the stimulating effects of chronic consumption, acute ethanol intake inhibits the metabolism of other drugs. Moreover, metabolism by CYP2E1 results in a significant release of free radicals which, in turn, diminishes reduced glutathione (GSH) and other defense systems against oxidative stress which plays a major pathogenic role in alcoholic liver disease. CYP1A2 and CYP3A4, two other perivenular P450s, also sustain the metabolism of ethanol, thereby contributing to MEOS activity and possibly liver injury. CYP2E1 has also a physiologic role which comprises gluconeogenesis from ketones, oxidation of fatty acids, and detoxification of xenobiotics other than ethanol. Excess of these physiological substrates (such as seen in obesity and diabetes) also leads to CYP2E1 induction and nonalcoholic fatty liver disease (NAFLD), which includes nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), with pathological lesions similar to those observed in alcoholic steatohepatitis. Increases of CYP2E1 and its mRNA prevail in the perivenular zone, the area of maximal liver damage. CYP2E1 up-regulation was also demonstrated in obese patients as well as in rat models of obesity and NASH. Furthermore, NASH is increasingly recognized as a precursor to more severe liver disease, sometimes evolving into "cryptogenic" cirrhosis. The prevalence of NAFLD averages 20% and that of NASH 2% to 3% in the general population, making these conditions the most common liver diseases in the United States. Considering the pathogenic role that up-regulation of CYP2E1 also plays in alcoholic liver disease (vide supra), it is apparent that a major therapeutic challenge is now to find a way to control this toxic process. CYP2E1 inhibitors oppose alcohol-induced liver damage, but heretofore available compounds are too toxic for clinical use. Recently, however, polyenylphosphatidylcholine (PPC), an innocuous mixture of polyunsaturated phosphatidylcholines extracted from soybeans (and its active component dilinoleoylphosphatidylcholine), were discovered to decrease CYP2E1 activity. PPC also opposes hepatic oxidative stress and fibrosis. It is now being tested clinically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., et al. (1993) · DNA and Cell Biology · doi:10.1089/dna.1993.12.1 · Cited by 1,655
Free-radical mechanisms in tissue injury
Slater, T. F. (1984) · Biochemical Journal · doi:10.1042/bj2220001 · Cited by 1,538
Cytochrome P-4502E1: its physiological and pathological role
Lieber, C. S. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.2.517 · Cited by 889
Self-citationHepatic Microsomal Ethanol-oxidizing System
Lieber, C. S., & DeCarli, L. M. (1970) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63099-6 · Cited by 812
Self-citationHayashi, S.-I., Watanabe, J., & Kawajiri, K. (1991) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123619 · Cited by 666
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M., & Liddle, C. (1998) · Hepatology · doi:10.1002/hep.510270121 · Cited by 614
Hepatic Microsomal Ethanol Oxidation: Hydrogen Peroxide Formation and the Role of Catalase
Thurman, R. G., Ley, H. G., & Scholz, R. (1972) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1972.tb01711.x · Cited by 599
Oxidative and reductive metabolism by cytochrome P450 2E1
Koop, D. R. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.2.1537462 · Cited by 560
Ethanol Oxidation by Hepatic Microsomes: Adaptive Increase after Ethanol Feeding
Lieber, C. S., & DeCarli, L. M. (1968) · Science · doi:10.1126/science.162.3856.917 · Cited by 556
Self-citationMicrosomal Ethanol‐Oxidizing System (MEOS): The First 30 Years (1968‐1998)–A Review
Lieber, C. S. (1999) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04217.x · Cited by 426
Self-citation
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
P450 Enzymes: Their Structure, Reactivity, and Selectivity—Modeled by QM/MM Calculations
Shaik, S., Cohen, S., Wang, Y., Chen, H., Kumar, D., & Thiel, W. (2010) · Chemical Reviews · doi:10.1021/cr900121s · Cited by 1,083
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Cellular and Molecular Mechanisms of Liver Injury
Malhi, H., & Gores, G. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.002 · Cited by 560
Metadata
- Authors
- Lieber, C. S.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2004-01
- Volume
- 36
- Issue
- 3-4
- Pages
- 511-529
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2104547476
- Cited by
- 259
- References
- 108
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Discovery of the Microsomal Ethanol Oxidizing System and Its Physiologic and Pathologic Role. https://app.cochat.ai/papers/10.1081/dmr-200033441
- The paper
- Lieber, C. S. (2004). The Discovery of the Microsomal Ethanol Oxidizing System and Its Physiologic and Pathologic Role. Drug Metabolism Reviews. https://doi.org/10.1081/dmr-200033441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.